ACE and chronic kidney disease: The lack of attenuation of CKD progression by dihydropyridine calcium channel blockers may be due to their association with increased albuminuria, even in patients under angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB), possibly through dilation of the glomerular afferent arteriole [21].